296 related articles for article (PubMed ID: 9552035)
1. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
Andrulis IL; Bull SB; Blackstein ME; Sutherland D; Mak C; Sidlofsky S; Pritzker KP; Hartwick RW; Hanna W; Lickley L; Wilkinson R; Qizilbash A; Ambus U; Lipa M; Weizel H; Katz A; Baida M; Mariz S; Stoik G; Dacamara P; Strongitharm D; Geddie W; McCready D
J Clin Oncol; 1998 Apr; 16(4):1340-9. PubMed ID: 9552035
[TBL] [Abstract][Full Text] [Related]
2. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
Bull SB; Ozcelik H; Pinnaduwage D; Blackstein ME; Sutherland DA; Pritchard KI; Tzontcheva AT; Sidlofsky S; Hanna WM; Qizilbash AH; Tweeddale ME; Fine S; McCready DR; Andrulis IL
J Clin Oncol; 2004 Jan; 22(1):86-96. PubMed ID: 14701769
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
4. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
5. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
[TBL] [Abstract][Full Text] [Related]
6. The association of HER-2/neu amplification with breast cancer recurrence.
Carr JA; Havstad S; Zarbo RJ; Divine G; Mackowiak P; Velanovich V
Arch Surg; 2000 Dec; 135(12):1469-74. PubMed ID: 11115354
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
[TBL] [Abstract][Full Text] [Related]
8. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes.
Mittra I; Redkar AA; Badwe RA
J Surg Oncol; 1995 Oct; 60(2):106-11. PubMed ID: 7564375
[TBL] [Abstract][Full Text] [Related]
10. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
[TBL] [Abstract][Full Text] [Related]
11. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
Torregrosa D; Bolufer P; Lluch A; López JA; Barragán E; Ruiz A; Guillem V; Munárriz B; García Conde J
Clin Chim Acta; 1997 Jun; 262(1-2):99-119. PubMed ID: 9204213
[TBL] [Abstract][Full Text] [Related]
13. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.
Schlotter CM; Vogt U; Bosse U; Mersch B; Wassmann K
Breast Cancer Res; 2003; 5(2):R30-6. PubMed ID: 12631396
[TBL] [Abstract][Full Text] [Related]
14. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
[TBL] [Abstract][Full Text] [Related]
15. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
16. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
17. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
[TBL] [Abstract][Full Text] [Related]
18. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
[TBL] [Abstract][Full Text] [Related]
19. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.
Riou G; Mathieu MC; Barrois M; Le Bihan ML; Ahomadegbe JC; Bénard J; Lê MG
Int J Cancer; 2001 Jul; 95(4):266-70. PubMed ID: 11400121
[TBL] [Abstract][Full Text] [Related]
20. Impact of Her-2 Neu overexpression on outcome of elderly women treated with wide local excision and breast irradiation for early stage breast cancer: an exploratory analysis.
Poltinnikov IM; Rudoler SB; Tymofyeyev Y; Kennedy J; Anne PR; Curran WJ
Am J Clin Oncol; 2006 Feb; 29(1):71-9. PubMed ID: 16462507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
